Enlivex Total Assets from 2010 to 2024

ENLV Stock

USD 1.14 0.07 6.54%

Enlivex Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 30.6 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2000-03-31

Previous Quarter

31 M

Current Value

31.9 M

Quarterly Volatility

25.5 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13.3 K, Total Revenue of 0.0 or Research Development of 20.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.58. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.

Check out the analysis of Enlivex Therapeutics Correlation against competitors.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Latest Enlivex Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Enlivex Therapeutics over the last few years. Total assets refers to the total amount of Enlivex Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enlivex Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Enlivex Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enlivex Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 36.83 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Total Assets

Timeline

Enlivex Total Assets Regression Statistics

	Arithmetic Mean	31,688,248
	Geometric Mean	12,248,120
	Coefficient Of Variation	103.54
	Mean Deviation	24,693,402
	Median	20,516,000
	Standard Deviation	32,809,805
	Sample Variance	1076.5T
	Range	102.2M
	R-Value	0.21
	Mean Square Error	1108.6T
	R-Squared	0.04
	Significance	0.45
	Slope	1,534,525
	Total Sum of Squares	15070.8T

Enlivex Total Assets History

	2024	30.6 M
	2023	36.8 M
	2022	67.6 M
	2021	95.1 M
	2020	40.4 M
	2019	17.6 M
	2018	11 M

Other Fundumenentals of Enlivex Therapeutics

Intangibles To Total Assets

Enlivex Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Treasury Stock	Long Term Debt	Good Will	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Capital Surpluse	Net Tangible Assets	Net Invested Capital	Net Working Capital	Capital Stock	Short Term Debt
Total Assets		1.0	0.73	0.46	0.81	0.6	0.47	0.37	0.03	0.56	0.57	-0.32	-0.23	0.12	0.62	-0.19	0.59	0.64	0.63	0.53	0.6
Total Stockholder Equity	1.0		0.75	0.47	0.77	0.63	0.41	0.33	0.01	0.6	0.6	-0.29	-0.18	0.08	0.58	-0.17	0.54	0.6	0.6	0.48	0.56
Accounts Payable	0.73	0.75		-0.01	0.46	0.7	0.05	0.32	0.01	0.65	0.69	-0.28	-0.05	-0.09	0.19	-0.02	0.06	0.1	0.07	0.11	0.21
Short Term Investments	0.46	0.47	-0.01		0.34	-0.03	0.35	-0.05	0.08	-0.04	-0.07	0.17	-0.02	0.12	0.64	-0.16	0.58	0.6	0.66	0.43	0.4
Total Liab	0.81	0.77	0.46	0.34		0.16	0.82	0.62	0.25	0.1	0.17	-0.51	-0.6	0.43	0.79	-0.31	0.82	0.83	0.81	0.83	0.83
Intangible Assets	0.6	0.63	0.7	-0.03	0.16		-0.22	0.06	-0.1	0.97	0.95	0.18	0.27	-0.22	-0.26	0.03	-0.19	-0.18	-0.18	-0.2	-0.16
Common Stock	0.47	0.41	0.05	0.35	0.82	-0.22		0.76	0.55	-0.35	-0.13	-0.31	-0.83	0.33	0.76	-0.5	0.89	0.86	0.84	0.97	0.84
Property Plant Equipment	0.37	0.33	0.32	-0.05	0.62	0.06	0.76		0.77	-0.14	0.17	-0.24	-0.87	-0.14	0.35	-0.43	0.6	0.49	0.45	0.77	0.67
Treasury Stock	0.03	0.01	0.01	0.08	0.25	-0.1	0.55	0.77		-0.31	-0.05	0.27	-0.76	-0.19	0.15	-0.38	0.46	0.2	0.2	0.56	0.29
Long Term Debt	0.56	0.6	0.65	-0.04	0.1	0.97	-0.35	-0.14	-0.31		0.88	0.1	0.44	-0.16	-0.28	0.13	-0.27	-0.23	-0.22	-0.31	-0.24
Good Will	0.57	0.6	0.69	-0.07	0.17	0.95	-0.13	0.17	-0.05	0.88		0.21	0.16	-0.24	-0.24	-0.03	-0.19	-0.13	-0.13	-0.14	-0.09
Net Debt	-0.32	-0.29	-0.28	0.17	-0.51	0.18	-0.31	-0.24	0.27	0.1	0.21		0.23	-0.15	-0.48	0.05	-0.36	-0.46	-0.39	-0.38	-0.59
Retained Earnings	-0.23	-0.18	-0.05	-0.02	-0.6	0.27	-0.83	-0.87	-0.76	0.44	0.16	0.23		-0.07	-0.52	0.23	-0.72	-0.6	-0.58	-0.83	-0.71
Net Receivables	0.12	0.08	-0.09	0.12	0.43	-0.22	0.33	-0.14	-0.19	-0.16	-0.24	-0.15	-0.07		0.37	-0.02	0.21	0.28	0.29	0.2	0.12
Total Current Assets	0.62	0.58	0.19	0.64	0.79	-0.26	0.76	0.35	0.15	-0.28	-0.24	-0.48	-0.52	0.37		-0.26	0.88	0.93	0.93	0.81	0.84
Capital Surpluse	-0.19	-0.17	-0.02	-0.16	-0.31	0.03	-0.5	-0.43	-0.38	0.13	-0.03	0.05	0.23	-0.02	-0.26		-0.35	-0.33	-0.33	-0.4	-0.3
Net Tangible Assets	0.59	0.54	0.06	0.58	0.82	-0.19	0.89	0.6	0.46	-0.27	-0.19	-0.36	-0.72	0.21	0.88	-0.35		0.94	0.94	0.96	0.89
Net Invested Capital	0.64	0.6	0.1	0.6	0.83	-0.18	0.86	0.49	0.2	-0.23	-0.13	-0.46	-0.6	0.28	0.93	-0.33	0.94		1.0	0.9	0.93
Net Working Capital	0.63	0.6	0.07	0.66	0.81	-0.18	0.84	0.45	0.2	-0.22	-0.13	-0.39	-0.58	0.29	0.93	-0.33	0.94	1.0		0.88	0.91
Capital Stock	0.53	0.48	0.11	0.43	0.83	-0.2	0.97	0.77	0.56	-0.31	-0.14	-0.38	-0.83	0.2	0.81	-0.4	0.96	0.9	0.88		0.91
Short Term Debt	0.6	0.56	0.21	0.4	0.83	-0.16	0.84	0.67	0.29	-0.24	-0.09	-0.59	-0.71	0.12	0.84	-0.3	0.89	0.93	0.91	0.91

Click cells to compare fundamentals

About Enlivex Therapeutics Financial Statements

Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	36.8 M	30.6 M
Intangibles To Total Assets	0.02	0.02

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC